roche holding ag - RHHVF
RHHVF
Close Chg Chg %
285.14 1.90 0.67%
Closed Market
287.04
+1.90 (0.67%)
Volume: 21.11K
Last Updated:
Nov 22, 2024, 1:51 PM EDT
Company Overview: roche holding ag - RHHVF
RHHVF Key Data
| Open $286.52 | Day Range 281.76 - 287.04 |
| 52 Week Range 233.12 - 340.88 | Market Cap N/A |
| Shares Outstanding NaN | Public Float 690.10M |
| Beta N/A | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS N/A |
| Yield N/A | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.86K |
RHHVF Performance
| 1 Week | 1.81% | ||
| 1 Month | -11.13% | ||
| 3 Months | -14.28% | ||
| 1 Year | 4.34% | ||
| 5 Years | -6.00% |
RHHVF Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Roche Holding Ag - RHHVF
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 62.14B | 68.69B | 66.26B | 65.34B | |
Sales Growth
| +0.46% | +10.55% | -3.54% | -1.39% | |
Cost of Goods Sold (COGS) incl D&A
| 17.42B | 21.55B | 19.72B | 17.60B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.86B | 4.86B | 4.00B | 3.87B | |
Depreciation
| 3.00B | 3.16B | 3.02B | 3.07B | |
Amortization of Intangibles
| 1.86B | 1.70B | 982.13M | 796.75M | |
COGS Growth
| -1.96% | +23.69% | -8.48% | -10.76% | |
Gross Income
| 44.71B | 47.14B | 46.54B | 47.74B | |
Gross Income Growth
| +1.44% | +5.42% | -1.28% | +2.58% | |
Gross Profit Margin
| +71.96% | +68.63% | +70.23% | +73.06% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 25.54B | 27.98B | 27.30B | 29.31B | |
Research & Development
| 12.95B | 14.99B | 14.71B | 14.72B | |
Other SG&A
| 12.60B | 12.98B | 12.59B | 14.59B | |
SGA Growth
| +2.88% | +9.52% | -2.40% | +7.35% | |
Other Operating Expense
| 282.33M | 260.32M | 201.03M | 233.68M | |
Unusual Expense
| 678.66M | 3.03B | 4.59B | 3.54B | |
EBIT after Unusual Expense
| 18.21B | 15.88B | 14.44B | 14.65B | |
Non Operating Income/Expense
| 1.40B | 3.53B | 3.33B | 1.97B | |
Non-Operating Interest Income
| - | - | - | 17.05M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 466.65M | 372.98M | 636.61M | 921.38M | |
Interest Expense Growth
| -25.20% | -20.07% | +70.68% | +44.73% | |
Gross Interest Expense
| 466.65M | 372.98M | 636.61M | 921.38M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 19.14B | 19.03B | 17.14B | 15.70B | |
Pretax Income Growth
| +14.39% | -0.57% | -9.95% | -8.38% | |
Pretax Margin
| +30.80% | +27.71% | +25.87% | +24.03% | |
Income Tax
| 3.09B | 2.69B | 2.93B | 1.92B | |
Income Tax - Current - Domestic
| 3.74B | 2.86B | 4.66B | 3.15B | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (649.89M) | (170.63M) | (1.74B) | (1.24B) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 16.05B | 16.34B | 14.17B | 13.75B | |
Minority Interest Expense
| 823.55M | 1.10B | 1.16B | 956.99M | |
Net Income
| 15.23B | 15.24B | 13.01B | 12.79B | |
Net Income Growth
| +12.14% | +0.04% | -14.64% | -1.62% | |
Net Margin Growth
| +24.51% | +22.18% | +19.63% | +19.58% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 15.23B | 15.24B | 13.01B | 12.79B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 15.23B | 15.24B | 13.01B | 12.79B | |
EPS (Basic)
| 17.8128 | 17.925 | 16.2567 | 16.0134 | |
EPS (Basic) Growth
| +12.27% | +0.63% | -9.31% | -1.50% | |
Basic Shares Outstanding
| 855.00M | 850.00M | 800.00M | 799.00M | |
EPS (Diluted)
| 17.6056 | 17.7153 | 16.2567 | 15.9138 | |
EPS (Diluted) Growth
| +12.02% | +0.62% | -8.23% | -2.11% | |
Diluted Shares Outstanding
| 865.00M | 860.00M | 800.00M | 804.00M | |
EBITDA
| 23.75B | 23.77B | 23.03B | 22.06B | |
EBITDA Growth
| +1.69% | +0.07% | -3.09% | -4.23% | |
EBITDA Margin
| +38.23% | +34.60% | +34.76% | +33.76% |
An error occurred while fetching the data.
SEC Filings for Roche Holding Ag - RHHVF
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
An error occurred while fetching the data.
Roche Holding Ag in the News
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Inside the race for a COVID-19 treatment pill
Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.